The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery

PNAS, 2004 · DOI: 10.1073/pnas.0402595101 · Published: June 8, 2004

Spinal Cord Injury Regenerative Medicine Neurology

Simple Explanation

This research investigates a potential therapy for spinal cord injuries using rolipram, a drug that enhances nerve regeneration. Rolipram works by increasing cAMP levels in nerve cells, which helps them overcome obstacles to regrowth after injury. The study found that rolipram, when given after a spinal cord injury in rats, encouraged nerve fibers to regrow into implanted spinal tissue. This regrowth was linked to better motor function and a reduction in the formation of scar tissue, which can hinder recovery. Because rolipram can be administered easily (s.c.) and shows benefits even after the injury, it's considered a promising candidate for treating spinal cord injuries.

Study Duration

4-6 weeks after rolipram or vehicle treatment (6-8 weeks after the spinal cord lesion)

Participants

12 adult rats

Evidence Level

Not specified

Key Findings

1
Rolipram overcomes inhibition by myelin in culture, promoting neurite outgrowth of DRG neurons.
2
Post-injury rolipram delivery enhances axonal regrowth into embryonic spinal cord transplants after hemisection lesions in rats.
3
Rolipram treatment attenuates reactive gliosis and significantly improves motor function in treated animals.

Research Summary

This study demonstrates that rolipram, a phosphodiesterase inhibitor, can promote axonal regeneration and functional recovery after spinal cord injury in rats. Rolipram overcomes inhibitors of regeneration, attenuates the glial scar, and enhances functional recovery. The research shows that rolipram promotes axonal growth into a transplant site following a hemisection lesion. This regrowth is associated with a significant improvement in motor function, suggesting the drug's potential as a therapeutic agent. Furthermore, the study reveals that rolipram attenuates reactive gliosis, which is the formation of glial scars, and is effective when delivered subcutaneously post-injury, making it a strong candidate for spinal cord injury therapy.

Practical Implications

Therapeutic Potential

Rolipram shows promise as a post-injury treatment option for spinal cord injuries due to its ability to promote axonal regeneration and functional recovery.

Attenuation of Gliosis

The finding that rolipram attenuates reactive gliosis suggests a potential mechanism for improving the environment for axonal regrowth after spinal cord injury.

Drug Delivery

The effectiveness of rolipram when delivered subcutaneously simplifies the delivery method and reduces the risk of further damage at the injury site.

Study Limitations

1
The study was conducted on rats, and the results may not be directly applicable to humans.
2
The optimal dosage of rolipram is critical, as higher doses were found to be ineffective.
3
The precise mechanisms by which rolipram promotes regeneration and functional recovery are not fully understood.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury